-- Announcement on Resolutions of the 8th Meeting of the 11th Board of Supervisors
Securities code: 600789 Securities abbreviation: Lukang Pharmaceutical Announcement number: 2025-040 Shandong Lukang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Eighth Meeting of the Eleventh Supervisory Board
The Company's Supervisory Committee and all supervisors guarantee that there are no false records, misleading statements or major omissions in this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The 8th meeting of the 11th Supervisory Board of Shandong Lukang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on-site at 2:00 pm on August 27, 2025 in the A1310 conference room of the company's high-tech park. Notice of this meeting was sent by email on August 18, 2025. There were 3 supervisors who were supposed to attend the meeting and 3 actually participated in the voting. The meeting was chaired by Mr. Wang Duping and complied with the relevant provisions of the Company Law and the Articles of Association.
After deliberation, the meeting adopted the following proposals by voting:
1. "2025 Semi-Annual Report and Summary"
The Board of Supervisors issued the following review opinions:
(1) The preparation and review procedures for the company’s 2025 semi-annual report comply with the provisions of laws, regulations, the company’s articles of association and the company’s internal management system;
(2) The content and format of the company’s 2025 semi-annual report comply with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the information contained can truly reflect the company’s operating results and financial status from January to June 2025 from all aspects;
(3) No personnel involved in the preparation and review of the semi-annual report were found to have violated confidentiality regulations;
(4) All supervisors believe that the information contained in the company’s 2025 semi-annual report does not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its content.
3 votes in favor, 0 votes against, 0 abstentions
2. "Proposal on Cancellation of the Board of Supervisors and Amendment to the Articles of Association"
In accordance with the provisions of the "Company Law of the People's Republic of China", "Stock Listing Rules of the Shanghai Stock Exchange", "Guidelines on the Articles of Association of Listed Companies" and other relevant laws, regulations and rules, and based on the actual situation of the company, there will no longer be a board of supervisors and supervisors, and the Audit Committee of the Board of Directors will exercise the powers of the board of supervisors. At the same time, the "Rules of Procedure of the Supervisory Board of Shandong Lukang Pharmaceutical Co., Ltd." will be abolished, and the "Articles of Association" will be revised.
Before the company's shareholders' meeting considers and approves this matter, the company's 11th Supervisory Board will continue to perform its functions in strict accordance with relevant laws and regulations and the provisions of the Articles of Association to safeguard the interests of the company and all shareholders. For details, please refer to the "Announcement on Cancellation of the Board of Supervisors, Revision of the Articles of Association, and Revision, Formulation and Abolition of Certain Governance Systems" published by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same day.
3 votes in favor, 0 votes against, 0 abstentions
The proposal still needs to be submitted to the company's shareholders' meeting for consideration.
Announcement hereby!
Board of Supervisors of Shandong Lukang Pharmaceutical Co., Ltd.
August 28, 2025